High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

Authors:
  • EJEt Janson
    Et Janson
  • ASA Sundin
    A Sundin
  • MSM Stridsberg
    M Stridsberg
  • ELE Lavenius
    E Lavenius
  • DGD Granberg
    D Granberg
  • BSB Skogseid
    B Skogseid
  • KOKe Oberg
    Ke Oberg
  • BEBk Eriksson
    Bk Eriksson

Abstract
OBJECTIVE: High-dose somatostatin analogue treatment has shown an antiproliferative effect in one study including patients with neuroendocrine tumours. To explore this therapeutic strategy further, we have studied the effect of a high-dose formula of octreotide, octreotide pamoate, in midgut carcinoid patients. DESIGN AND METHODS: Twelve patients with advanced midgut carcinoid tumours with a median duration of disease of more than 5 years were included. All were in a progressive state despite several previous treatment modalities. Octreotide pamoate (160 mg) was given as an intramuscular injection every 2 weeks for 2 months and then monthly. Radiological and biochemical responses were monitored. RESULTS: Tumour size and biochemical markers were stabilised for a median of 12 months in 75% of the patients. Ten patients had symptomatic improvement of flush and diarrhoea. CONCLUSION: In this group of patients with advanced midgut carcinoid tumours and progressive disease, octreotide pamoate managed to improve symptoms, and stabilise hormone production and tumour growth in 75% of the patients. We believe that high-dose treatment with somatostatin analogues can be an important addition to the therapeutic arsenal for patients with advanced progressive midgut carcinoid tumours.